WHAT IS PARACETAMOL 125MG + PHENYLEPHRINE 2.5MG + CPM 1MG SUSPENSION AND ITS COMPOSITION? Multi-ingredient pharmaceutical preparation provided in the form of a liquid formulation comprising Paracetamol, Phenylephrine and Chlorpheniramine Maleate (CPM). This pharmaceutical formulation is prepared in the form of an oral suspension, in which the actives with required excipients are dispersed in a liquid base to develop a physically stable liquid.
The mentioned formula contains: Paracetamol 125MG, Phenylephrine 2.5MG, CPM 1MG As the dosage form is a suspension – formulation development of suspension includes attention to particle-size distribution, wetting, dispersion and sedimentation behavior, viscosity, redispersibility, pH, and physical stability.
It may also include appropriate pharmaceutical grade suspending agents, wetting agents, sweeteners, flavouring agents, buffering agents, preservatives, viscosity increasing agents, and other excipients, depending on the final product specifications. The choice of each of the ingredients should be made based on its compatibility and the physical properties of the finished suspension.
1. Suspension particles within liquid All other hair components are suspended in a liquid within a suspension. As such, consistency while in storage, plus redispersion after the product has been allowed to settle, should also be taken into consideration.
Producer of PARACETAMOL 125MG + PHENYLEPHRINE 2.5MG + CPM 1MG SUSPENSION The formulation is prepared with the evaluation of the active ingredients Physicochemical properties begin with the assessment of the particle size, solubility, density, wettability, moisture content and packaging compatibility of the proposed excipients in preformulation.
Control of particle-size distribution of Paracetamol could be required for optimum dispersion in the liquid vehicle. Phenylephrine and Chlorpheniramine Maleate may be added as appropriate, in relation to their solubility and formulation properties.
Suspending agents may be required to provide the structured vehicle, capable of holding dispersed particles throughout the formulation. Wetting agents can be used where necessary to ensure that powder ingredients disperse evenly into the liquid phase.
Viscosity selection is a key formulation factor. Too low viscosity can lead to rapid settling, while too high viscosity can affect manufacturing, filling, and dispensing. In practice, the suspension system is usually optimized during formulation-development trials.
Sweetening and flavoring constituents may be added where appropriate to the final product formula. Buffering agents may be used where appropriate in order to satisfy the required pH range and ensure formula stability.
All raw materials are identified, sampled, tested, and approved before manufacturing. Approved ingredients are dispensed in accordance with the master manufacturing formula using calibrated equipment.
The medium vehicle is prepared in the previously selected suitable manufacturing vessel. Suspension agents and other water-soluble excipients are then usually presoaked or dissolved if necessary during processing.
The active ingredients are dispersed when necessary, by the use of the appropriate size fragments, sieving, levigation or any particle-size-control process. This improves dispersion and prevents the chance of any nonspecific agglomerates.
Powder ingredients are added slowly to the bulk vehicle, prepared first in small quantities then larger quantities, with constant stirring. The powders are uniformly dispersed to produce a homogenous bulk suspension.
Depending on the formulation design, an enhanced physical and dispersed blend may be achieved by means of homogenization or high-shear mixing. The speed of mixing, time, temperature, and sequence of addition are all developed and optimized during formulation development and are then closely followed during production.
Once the active drug ingredients and excipients are thoroughly mixed, the bulk suspension may then be deaerated, adjusted in volume, or filtered in certain liquid components if needed.
Checks in process may include appearance, pH, viscosity, bulk volume, sedimentation properties and homogeneity. These are controls that need to be checked on the suspension prior to filling so that the finished suspension is consistent.
PARACETAMOL 125MG + PHENYLEPHRINE 2.5MG + CPM 1MG SUSPENSION testing in respect of quality control (chemical, physical and microbiological) shall be carried out in accordance with the approved specification of the product.
Analytical tests can include, Estimation / assay of Paracetamol, Phenylephrine and Chlorpheniramine Maleate, Related substances, As well as any other appropriate chemical tests and parameters. The tested chemical methods should be validated in order to ensure accurate quantification of each active substance in the multi-component formula.
Physical testing may include appearance, color, odor, pH, viscosity, particle-size distribution, sedimentation volume, redispersibility, and fill-volume evaluation.
REDISPERSIBILITY - One of the property of a suspension formulation. During stability studies or product development it is often possible to test how the suspension is affected by a period of controlled storage, and to observe whether it is re-dispersed after an agreed period of standard agitation.
The microbiological quality of the aqueous pharmaceutical suspension is also a concern. Proper testing for the micro-organisms should be carried out according to the relevant product specification. If the product contains a preservative, the system of preservation of the formulation may also be necessary to suitably evaluate.
Quality assurance enables these testing activities with raw-material qualification, equipment calibration, process validation, batch documentation, environmental monitoring, deviation handling, change control and batch-release processes.
Stability testing will support to assure that the products, as specified in the specifications, released for sale or for use, after storage under the defined conditions, continue to meet the specifications.
At specified intervals, the appearance, color, odor, pH, viscosity, assay, character of degradation, sedimentation pattern, dispersibility, microbiological quality, and other suitable properties of the stability samples are examined.
Special care must be given to suspension stability, as physical alteration might happen during storage. Tendency for particles to settle, changes in viscosity, agglomeration, phase separation, and physical appearance variations might be observe in development and stability testing.
Manufacturing Packaging is chosen according to the formulation's stability needs and how it is to be dispensed. There is the possibility of using pharmaceutical grade bottles of compatible material with appropriate closures and measuring devices.
Container-closure compatibility should be considered to confirm that the suspension is not incompatible with the container. The closure system should adequately protect the suspension from contamination and environmental factors.
Packchecks are carried out during packing to ensure minimum fill volumes in individual units. The product is properly capped and sealed, labeled, batch coded, and packed into secondary packaging.
PARACETAMOL 125MG + PHENYLEPHRINE 2.5MG + CPM 1MG SUSPENSION. This product is a part of a diversified pharmaceutical portfolio which includes tablets, capsules, oral drops, syrups, dry syrups, suspensions, creams, and many other forms. Suspending form of the product calls for special kinds of attention to be given on the particle dispersion, viscosity, dispersibility, sedimentation rate, and the pack performance.
A well-managed pharmaceutical product development process is a combined effort of formulation group, production, quality-control laboratories, quality-assurance people, packaging department, and regulatory department. Uniform specifications and written procedures ensure that the product of all batches conforms to quality standards.
In the case of liquid suspensions, good control over particles and distribution of particles is essential. The right choice of excipients, homogenisation and analytical controls, microbiological quality, stability and packaging are all factors that will affect the final product.
Those organizations that want to add PCD Pharma Franchise products may also want to consider this PCD Pharma Franchise Combination suspension along with a well-planned series of oral liquid form products. Proper manufacturing process, standard quality-control protocols, stability testing and aligned packaging design are a good way to ensure the production of a trusted pharmaceutical product line.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech